APO Research
Talk to an analyst

APO RESEARCH · REPORT

Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Analysis and Forecast 2026-2032

19 December 2025191 pages

Choose your research edition.

Industry ResearchPost-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Post-Polycythemia Vera Myelofibrosis (PPV-MF) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Post-Polycythemia Vera Myelofibrosis (PPV-MF) include Novartis AG, Merck & Co Inc, AbbVie Inc, Sun Pharma Advanced Research Company Ltd, Promedior Inc, NS Pharma Inc, MEI Pharma Inc, MedImmune LLC and JW Pharmaceutical Corp, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Post-Polycythemia Vera Myelofibrosis (PPV-MF), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Post-Polycythemia Vera Myelofibrosis (PPV-MF), also provides the revenue of main regions and countries. Of the upcoming market potential for Post-Polycythemia Vera Myelofibrosis (PPV-MF), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Post-Polycythemia Vera Myelofibrosis (PPV-MF) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Post-Polycythemia Vera Myelofibrosis (PPV-MF) revenue, projected growth trends, production technology, application and end-user industry.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Company

Novartis AG

Merck & Co Inc

AbbVie Inc

Sun Pharma Advanced Research Company Ltd

Promedior Inc

NS Pharma Inc

MEI Pharma Inc

MedImmune LLC

JW Pharmaceutical Corp

Italfarmaco SpA

Incyte Corp

Gilead Sciences Inc

F. Hoffmann-La Roche Ltd

CTI BioPharma Corp

Celgene Corp

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Type

Idelalisib

Givinostat

Glasdegib

Durvalumab

IMG-7289

Others

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Application

Hospital

Clinic

Others

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Post-Polycythemia Vera Myelofibrosis (PPV-MF) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Post-Polycythemia Vera Myelofibrosis (PPV-MF).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Post-Polycythemia Vera Myelofibrosis (PPV-MF) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Post-Polycythemia Vera Myelofibrosis (PPV-MF) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Post-Polycythemia Vera Myelofibrosis (PPV-MF) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Idelalisib Major Player Table 3. Givinostat Major Player Table 4. Glasdegib Major Player Table 5. Durvalumab Major Player Table 6. IMG-7289 Major Player Table 7. Others Major Player Table 8. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Major Player Table 10. Clinic Major Player Table 11. Others Major Player Table 12. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Trends Table 13. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Drivers Table 14. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Opportunities and Challenges Table 15. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Restraints Table 16. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Region (2021-2026) Table 19. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Region (2027-2032) Table 21. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Players (2021-2026) Table 23. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Key Players Headquarters & Area Served Table 25. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players, Product Type & Application Table 26. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Type (2021-2026) Table 33. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Type (2027-2032) Table 34. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Application (2021-2026) Table 38. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Application (2027-2032) Table 39. Novartis AG Company Information Table 40. Novartis AG Business Overview Table 41. Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 43. Novartis AG Recent Development Table 44. Merck & Co Inc Company Information Table 45. Merck & Co Inc Business Overview Table 46. Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 48. Merck & Co Inc Recent Development Table 49. AbbVie Inc Company Information Table 50. AbbVie Inc Business Overview Table 51. AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 53. AbbVie Inc Recent Development Table 54. Sun Pharma Advanced Research Company Ltd Company Information Table 55. Sun Pharma Advanced Research Company Ltd Business Overview Table 56. Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 58. Sun Pharma Advanced Research Company Ltd Recent Development Table 59. Promedior Inc Company Information Table 60. Promedior Inc Business Overview Table 61. Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 63. Promedior Inc Recent Development Table 64. NS Pharma Inc Company Information Table 65. NS Pharma Inc Business Overview Table 66. NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 68. NS Pharma Inc Recent Development Table 69. MEI Pharma Inc Company Information Table 70. MEI Pharma Inc Business Overview Table 71. MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 73. MEI Pharma Inc Recent Development Table 74. MedImmune LLC Company Information Table 75. MedImmune LLC Business Overview Table 76. MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 78. MedImmune LLC Recent Development Table 79. JW Pharmaceutical Corp Company Information Table 80. JW Pharmaceutical Corp Business Overview Table 81. JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 83. JW Pharmaceutical Corp Recent Development Table 84. Italfarmaco SpA Company Information Table 85. Italfarmaco SpA Business Overview Table 86. Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 88. Italfarmaco SpA Recent Development Table 89. Incyte Corp Company Information Table 90. Incyte Corp Business Overview Table 91. Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 93. Incyte Corp Recent Development Table 94. Gilead Sciences Inc Company Information Table 95. Gilead Sciences Inc Business Overview Table 96. Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 98. Gilead Sciences Inc Recent Development Table 99. F. Hoffmann-La Roche Ltd Company Information Table 100. F. Hoffmann-La Roche Ltd Business Overview Table 101. F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 103. F. Hoffmann-La Roche Ltd Recent Development Table 104. CTI BioPharma Corp Company Information Table 105. CTI BioPharma Corp Business Overview Table 106. CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 108. CTI BioPharma Corp Recent Development Table 109. Celgene Corp Company Information Table 110. Celgene Corp Business Overview Table 111. Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio Table 113. Celgene Corp Recent Development Table 114. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026) & (US$ Million) Table 115. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2027-2032) & (US$ Million) Table 116. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026) & (US$ Million) Table 117. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2027-2032) & (US$ Million) Table 118. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021-2026) & (US$ Million) Table 120. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (US$ Million) & (2027-2032) Table 121. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026) & (US$ Million) Table 122. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2027-2032) & (US$ Million) Table 123. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026) & (US$ Million) Table 124. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2027-2032) & (US$ Million) Table 125. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021-2026) & (US$ Million) Table 127. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (US$ Million) & (2027-2032) Table 128. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026) & (US$ Million) Table 129. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2027-2032) & (US$ Million) Table 130. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026) & (US$ Million) Table 131. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026) & (US$ Million) Table 133. Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2027-2032) & (US$ Million) Table 134. Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026) & (US$ Million) Table 135. Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2027-2032) & (US$ Million) Table 136. Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 137. Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Region (US$ Million) & (2021-2026) Table 138. Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Region (US$ Million) & (2027-2032) Table 139. SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026) & (US$ Million) Table 140. SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2027-2032) & (US$ Million) Table 141. SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026) & (US$ Million) Table 142. SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2027-2032) & (US$ Million) Table 143. SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021-2026) & (US$ Million) Table 145. SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (US$ Million) & (2027-2032) Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Image Figure 2. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Idelalisib Image Figure 5. Givinostat Image Figure 6. Glasdegib Image Figure 7. Durvalumab Image Figure 8. IMG-7289 Image Figure 9. Others Image Figure 10. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (US$ Million) & (2021-2032) Figure 16. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Type (2021-2032) Figure 23. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Application (2021-2032) Figure 26. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type (2021-2032) Figure 28. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Application (2021-2032) Figure 29. North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Country (2021-2032) Figure 30. United States Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type (2021-2032) Figure 35. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Application (2021-2032) Figure 36. Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Country (2021-2032) Figure 37. Germany Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type (2021-2032) Figure 47. China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Application (2021-2032) Figure 48. Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type (2021-2032) Figure 50. Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Application (2021-2032) Figure 51. Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Region (2021-2032) Figure 52. Japan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type (2021-2032) Figure 60. SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Application (2021-2032) Figure 61. SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Country (2021-2032) Figure 62. Brazil Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Idelalisib
  • Givinostat
  • Glasdegib
  • Durvalumab
  • IMG-7289
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis AG
  • Merck & Co Inc
  • AbbVie Inc
  • Sun Pharma Advanced Research Company Ltd
  • Promedior Inc
  • NS Pharma Inc
  • MEI Pharma Inc
  • MedImmune LLC
  • JW Pharmaceutical Corp
  • Italfarmaco SpA
  • Incyte Corp
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • CTI BioPharma Corp
  • Celgene Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Type
  3. 1.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Idelalisib
  5. 1.2.3 Givinostat
  6. 1.2.4 Glasdegib
  7. 1.2.5 Durvalumab
  8. 1.2.6 IMG-7289
  9. 1.2.7 Others
  10. 1.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Application
  11. 1.3.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital
  13. 1.3.3 Clinic
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Dynamics
  1. 2.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Trends
  2. 2.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Drivers
  3. 2.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Opportunities and Challenges
  4. 2.4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Perspective (2021-2032)
  2. 3.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Growth Trends by Region
  3. 3.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2021-2026)
  5. 3.2.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Players
  2. 4.1.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Players (2021-2026)
  3. 4.1.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Key Players Headquarters & Area Served
  7. 4.4 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players, Product Type & Application
  8. 4.5 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market CR5 and HHI
  11. 4.6.3 2025 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Tier 1, Tier 2, and Tier 3
5 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Type
  1. 5.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2032)
  3. 5.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Type (2021-2032)
6 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Application
  1. 6.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2032)
  3. 6.3 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Merck & Co Inc
  8. 7.2.1 Merck & Co Inc Company Information
  9. 7.2.2 Merck & Co Inc Business Overview
  10. 7.2.3 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  12. 7.2.5 Merck & Co Inc Recent Developments
  13. 7.3 AbbVie Inc
  14. 7.3.1 AbbVie Inc Company Information
  15. 7.3.2 AbbVie Inc Business Overview
  16. 7.3.3 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  18. 7.3.5 AbbVie Inc Recent Developments
  19. 7.4 Sun Pharma Advanced Research Company Ltd
  20. 7.4.1 Sun Pharma Advanced Research Company Ltd Company Information
  21. 7.4.2 Sun Pharma Advanced Research Company Ltd Business Overview
  22. 7.4.3 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  24. 7.4.5 Sun Pharma Advanced Research Company Ltd Recent Developments
  25. 7.5 Promedior Inc
  26. 7.5.1 Promedior Inc Company Information
  27. 7.5.2 Promedior Inc Business Overview
  28. 7.5.3 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  30. 7.5.5 Promedior Inc Recent Developments
  31. 7.6 NS Pharma Inc
  32. 7.6.1 NS Pharma Inc Company Information
  33. 7.6.2 NS Pharma Inc Business Overview
  34. 7.6.3 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  36. 7.6.5 NS Pharma Inc Recent Developments
  37. 7.7 MEI Pharma Inc
  38. 7.7.1 MEI Pharma Inc Company Information
  39. 7.7.2 MEI Pharma Inc Business Overview
  40. 7.7.3 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  42. 7.7.5 MEI Pharma Inc Recent Developments
  43. 7.8 MedImmune LLC
  44. 7.8.1 MedImmune LLC Company Information
  45. 7.8.2 MedImmune LLC Business Overview
  46. 7.8.3 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  48. 7.8.5 MedImmune LLC Recent Developments
  49. 7.9 JW Pharmaceutical Corp
  50. 7.9.1 JW Pharmaceutical Corp Company Information
  51. 7.9.2 JW Pharmaceutical Corp Business Overview
  52. 7.9.3 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  53. 7.9.4 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  54. 7.9.5 JW Pharmaceutical Corp Recent Developments
  55. 7.10 Italfarmaco SpA
  56. 7.10.1 Italfarmaco SpA Company Information
  57. 7.10.2 Italfarmaco SpA Business Overview
  58. 7.10.3 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  60. 7.10.5 Italfarmaco SpA Recent Developments
  61. 7.11 Incyte Corp
  62. 7.11.1 Incyte Corp Company Information
  63. 7.11.2 Incyte Corp Business Overview
  64. 7.11.3 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  66. 7.11.5 Incyte Corp Recent Developments
  67. 7.12 Gilead Sciences Inc
  68. 7.12.1 Gilead Sciences Inc Company Information
  69. 7.12.2 Gilead Sciences Inc Business Overview
  70. 7.12.3 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  72. 7.12.5 Gilead Sciences Inc Recent Developments
  73. 7.13 F. Hoffmann-La Roche Ltd
  74. 7.13.1 F. Hoffmann-La Roche Ltd Company Information
  75. 7.13.2 F. Hoffmann-La Roche Ltd Business Overview
  76. 7.13.3 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  77. 7.13.4 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  78. 7.13.5 F. Hoffmann-La Roche Ltd Recent Developments
  79. 7.14 CTI BioPharma Corp
  80. 7.14.1 CTI BioPharma Corp Company Information
  81. 7.14.2 CTI BioPharma Corp Business Overview
  82. 7.14.3 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  83. 7.14.4 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  84. 7.14.5 CTI BioPharma Corp Recent Developments
  85. 7.15 Celgene Corp
  86. 7.15.1 Celgene Corp Company Information
  87. 7.15.2 Celgene Corp Business Overview
  88. 7.15.3 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
  90. 7.15.5 Celgene Corp Recent Developments
8 North America
  1. 8.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (2021-2032)
  2. 8.2 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2032)
  3. 8.2.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026)
  4. 8.2.2 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2027-2032)
  5. 8.3 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type (2021-2032)
  6. 8.4 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2032)
  7. 8.4.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026)
  8. 8.4.2 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2027-2032)
  9. 8.5 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Application (2021-2032)
  10. 8.6 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country
  11. 8.6.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021-2026)
  13. 8.6.3 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (2021-2032)
  2. 9.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2027-2032)
  5. 9.3 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2027-2032)
  9. 9.5 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country
  11. 9.6.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (2021-2032)
  2. 10.2 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2032)
  3. 10.2.1 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026)
  4. 10.2.2 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2027-2032)
  5. 10.3 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type (2021-2032)
  6. 10.4 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2032)
  7. 10.4.1 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026)
  8. 10.4.2 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2027-2032)
  9. 10.5 China Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (2021-2032)
  2. 11.2 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2027-2032)
  5. 11.3 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2027-2032)
  9. 11.5 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country
  11. 11.6.1 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue (2021-2032)
  2. 12.2 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country
  11. 12.6.1 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst